A Randomised Controlled Study of Semaglutide Versus Placebo in Patients With Obesity and Atrial Fibrillation: The SEMOAF Trial (Trial Not Registered)

This trial is Coming soon

Registration number Trial Not Registered

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia globally contributing significantly to cardiovascular morbidity and mortality. Obesity is a well-established modifiable risk factor for AF and is present in 2/3 of patients with AF. The SEMOAF study aims to randomise 220 patients with AF and overweight/obesity to semaglutide 2.4 mg weekly vs placebo to determine the impact of weight loss on AF recurrence and burden.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Cardiology program.

Trial phase

Phase 4

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Peter Kistler

Key inclusion data

Age 18 to 80 years. ECG diagnosed paroxysmal AF with 2 episodes in last 6 months, persistent AF on rhythm control or those with recurrent AF more than 3 months post ablation. BMI ≥27 kg/m2. Ability to provide informed consent before any trial-related activities.

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.